Gregg Huber Alton

r. Gregg Huber ALTON has been serving as a director and member of the audit committee of Novavax, Inc., (stock code: NVAX) since November 2020 and December 2020, respectively. He has been serving as a director, the chair of the corporate governance and nominating committee as well as the audit committee, and a member of the compensation committee of Corcept Therapeutics Incorporated, (stock code: CORT) since March 2020. Further, Mr. Alton has been serving as a director, member of the audit committee, and the chair of the nominating and corporate governance committee of Enochian Biosciences Inc., a pharmaceuticals company listed on the NASDAQ Stock Exchange (stock code: ENOB) since December 2019.

Mr. Alton held several positions in Gilead Sciences, Inc., a biopharmaceutical company listed on the NASDAQ Stock Exchange in the United States (stock code: GILD) from October 1999 to January 2020, including general counsel, chief patent officer, interim chief executive officer, and senior advisor of Gilead Sciences, Inc., and he was responsible for the company’s government affairs, public affairs, patient outreach, and engagement initiatives, and led the company’s international commercial operations and corporate affairs, groups. Mr. Alton was an associate at Cooley Godward, LLP, a law firm, between November 1993 to December 1996, and June 1998 to October 1999. He was an associate attorney at Mintz Levin P.C., a law firm, from January 1997 to May 1998.

Mr. Alton obtained his Bachelor of Arts with a major in legal studies from the University of California in Berkeley, the United States in May 1989, and a Doctor of Jurisprudence from The Leland Stanford Junior University in the United States in June 1993.Mr. Alton was also admitted as an attorney and counselor at law by the supreme court of the state of California between June 1994 and July 2019.